Literature DB >> 6189954

Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon.

O T Preble, K Rothko, J H Klippel, R M Friedman, M I Johnston.   

Abstract

The interferon (IFN)-induced enzyme 2-5A synthetase was elevated in mononuclear cells from both serum IFN-positive and -negative systemic lupus erythematosus (SLE) patients. This suggests that a much higher percentage of patients than previously thought produce endogenous IFN. These results may partly explain findings that mononuclear cells from SLE patients are deficient in IFN production in vitro in response to certain IFN inducers. Although normal lymphocytes can produce an acid-labile alpha IFN after stimulation with C. parvum in vitro, the reason for endogenous production of this unusual alpha IFN by SLE patients remains unknown.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189954      PMCID: PMC2187063          DOI: 10.1084/jem.157.6.2140

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Authors:  H Heremans; A Billiau; A Colombatti; J Hilgers; P de Somer
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

2.  Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice.

Authors:  B R Brodeur; T C Merigan
Journal:  J Immunol       Date:  1974-10       Impact factor: 5.422

3.  Electrophoretically pure mouse interferon has priming but no blocking activity in poly(I.C)-induced cells.

Authors:  J de Maeyer-Guignard; A Cachard; E de Maeyer
Journal:  Virology       Date:  1980-04-15       Impact factor: 3.616

4.  Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.

Authors:  J J Hooks; G W Jordan; T Cupps; H M Moutsopoulos; A S Fauci; A L Notkins
Journal:  Arthritis Rheum       Date:  1982-04

5.  Assay of (2'-5')-oligoadenylic acid synthetase levels in cells and tissues: a convenient poly(I) . poly(C) paper-bound enzyme assay.

Authors:  G R Stark; R E Brown; I M Kerr
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases.

Authors:  A Schattner; D Wallach; G Merlin; T Hahn; S Levin; M Revel
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

7.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

8.  Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease.

Authors:  E G Engleman; G Sonnenfeld; M Dauphinee; J S Greenspan; N Talal; H O McDevitt; T C Merigan
Journal:  Arthritis Rheum       Date:  1981-11

9.  Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  P A Neighbour; A I Grayzel
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

10.  Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon.

Authors:  O T Preble; R J Black; R M Friedman; J H Klippel; J Vilcek
Journal:  Science       Date:  1982-04-23       Impact factor: 47.728

View more
  26 in total

1.  Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells.

Authors:  H Vallin; S Blomberg; G V Alm; B Cederblad; L Rönnblom
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus.

Authors:  J H Klippel; S Carette; O T Preble; R M Friedman; P M Grimley
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

3.  Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.

Authors:  G Rappocciolo; J F Toso; D J Torpey; P Gupta; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

4.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

5.  Induction and measurement of 2',5'-oligoadenylate synthetase in Madin-Darby bovine kidney cells and in cattle.

Authors:  E C Short; R W Fulton
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

6.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

7.  Tumour necrosis factor production and cell-mediated immunity in anorexia nervosa.

Authors:  A Schattner; M Steinbock; R Tepper; A Schonfeld; N Vaisman; T Hahn
Journal:  Clin Exp Immunol       Date:  1990-01       Impact factor: 4.330

8.  (2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections.

Authors:  A Schattner; G Merlin; V Bregman; T Hahn; S Levin; M Revel; D Wallach
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

9.  Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome.

Authors:  T H Bacon; F Ozbakir; C A Elms; A M Denman
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

10.  Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis.

Authors:  Anna-Marie Fairhurst; Chun Xie; Yuyang Fu; Andrew Wang; Christopher Boudreaux; Xin J Zhou; Ricardo Cibotti; Anthony Coyle; John E Connolly; Edward K Wakeland; Chandra Mohan
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.